Check-Cap Ltd. is a clinical-stage medical diagnostics company headquartered in Isfiya, Israel, developing capsule-based screening technology for gastrointestinal imaging. The company's primary focus is on creating non-invasive diagnostic solutions that utilize capsule-based platforms to detect abnormalities in the digestive system. Founded in 2004 and listed on Nasdaq, Check-Cap operates within the medical devices and diagnostics sector, specifically addressing applications in areas classified under X-ray apparatus and related irradiation technology.
The company is currently in clinical development stages, meaning its primary revenue streams have not yet been established from commercialized products. Check-Cap's business model centers on the advancement and potential commercialization of its proprietary capsule technology for screening applications. The company's operations are based in Israel, with its development activities focused on bringing its diagnostic platform through clinical trials and regulatory approval processes.
As a clinical-stage company with a market capitalization of approximately $0.0 billion, Check-Cap operates at an early development phase of the medical device industry. The company's scale reflects its status as a pre-revenue or early-revenue diagnostics developer rather than an established commercial operation. Specific employee count and detailed geographic reach information are not readily available, though the organization maintains its primary operational base in Israel while pursuing regulatory pathways in key markets.
No 10-K filings found.